

Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile

<https://marketpublishers.com/r/MEEE97CE444EN.html>

Date: April 2011

Pages: 63

Price: US\$ 5,700.00 (Single User License)

ID: MEEE97CE444EN

Abstracts

Introduction

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Mitsubishi Tanabe's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Your key questions answered

Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector

See how the launch of pipeline products will generate modest growth and offset

expiring product declines for the company

Contents

Executive Summary

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2003–15

Operating costs and profit analysis

Mitsubishi Tanabe: PharmaVitae forecasts at a glance

Strategic insight

2007: Tanabe and Mitsubishi merge amid a wave of Japanese consolidation

2009–15: greater scale but slow growth

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

About

ABOUT THIS PROFILE

- PharmaVitae Explorer database
- Chapter structure
 - Quarterly update
 - Company introduction
 - Company sales
 - Company financials
 - Key products and competitors
- Data sourcing
 - Analyst consensus

QUARTERLY UPDATE

- Latest prescription pharma product news
 - Q2 2010
 - Q1 2010
 - Q4 2009
 - Q3 2009
- Latest corporate news
 - Q2 2010
 - Q1 2010
 - Q3 2009
- Future product milestones

COMPANY INTRODUCTION

- Key findings
- Background
- M&A history
 - Merger of Mitsubishi Pharma and Tanabe Seiyaku
 - M&A history: Mitsubishi Pharma
 - M&A history: Tanabe Seiyaku
 - M&A strategy
- Current corporate structure
 - Pharmaceuticals segment
 - Other business segment

COMPANY SALES

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2003–15

Product analysis

Product analysis, 2003–09

Product analysis, 2009–15

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Explanation of launch/core/expiry analysis

Launch analysis, 2009–15

Core analysis, 2009–15

Expiry analysis, 2009–15

Launch/core/expiry configuration, 2009–15

Molecule type analysis

Externalization analysis

COMPANY FINANCIALS

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09

Operating costs and profit analysis

Operating costs and profit analysis, 2003–09

Operating cost ratio and profit margin analysis, 2003–09

Operating cost ratio and profit margin analysis, 2009–15

Operating costs and profit analysis, 2009–15

APPENDIX

References

I would like to order

Product name: Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile

Product link: <https://marketpublishers.com/r/MEEE97CE444EN.html>

Price: US\$ 5,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MEEE97CE444EN.html>